

# Cindy Neuzillet

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/975151/publications.pdf>

Version: 2024-02-01

76  
papers

3,476  
citations

236925

25  
h-index

214800

47  
g-index

86  
all docs

86  
docs citations

86  
times ranked

7107  
citing authors

#	ARTICLE	IF	CITATIONS
1	Patient healthcare trajectories of intrahepatic cholangiocarcinoma in France: A nationwide retrospective analysis. <i>Lancet Regional Health - Europe</i> , The, 2022, 15, 100324.	5.6	7
2	The Immune Landscape of Human Pancreatic Ductal Carcinoma: Key Players, Clinical Implications, and Challenges. <i>Cancers</i> , 2022, 14, 995.	3.7	28
3	First-line chemotherapy plus immunotherapy in biliary tract cancer. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, , .	8.1	2
4	Rational testing for gene fusion in colorectal cancer: MSI and RAS-BRAF wild-type metastatic colorectal cancer as target population for systematic screening. <i>European Journal of Cancer</i> , 2022, 170, 85-90.	2.8	2
5	Adapted physical activity in patients (Pts) with advanced pancreatic cancer (APACaP): Results from a prospective national randomized GERCOR trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4007-4007.	1.6	8
6	Nutrition and physical activity: French intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC, SFP-APA,) Tj ETQq0.0 0 rgBT #overlock 1	1.0	0
7	Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial. <i>European Journal of Cancer</i> , 2021, 143, 55-63.	2.8	32
8	Impact of the IDEA Collaboration Study Results on Clinical Practice in France for Patients With Stage III Colon Cancer: A National GERCOR - PRODIGE Survey. <i>Clinical Colorectal Cancer</i> , 2021, 20, 79-83.e4.	2.3	4
9	Pharmacologic Normalization of Pancreatic Cancer-Associated Fibroblast Secretome Impairs Prometastatic Cross-Talk With Macrophages. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 11, 1405-1436.	4.5	21
10	Microbiome and pancreatic ductal adenocarcinoma. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101589.	1.5	18
11	Prognostic value of intratumoral <i>Fusobacterium nucleatum</i> and association with immune-related gene expression in oral squamous cell carcinoma patients. <i>Scientific Reports</i> , 2021, 11, 7870.	3.3	31
12	Biomarkers in Hepatobiliary Cancers: What Is Useful in Clinical Practice?. <i>Cancers</i> , 2021, 13, 2708.	3.7	19
13	Infigratinib in pretreated cholangiocarcinoma with FGFR2 fusions or rearrangements. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 773-775.	8.1	5
14	Immune Therapy for Liver Cancers. <i>Cancers</i> , 2020, 12, 77.	3.7	49
15	Cancer-Associated Fibroblasts: Accomplices in the Tumor Immune Evasion. <i>Cancers</i> , 2020, 12, 2969.	3.7	21
16	FOLFIRINOX Deâ€Escalation in Advanced Pancreatic Cancer: A Multicenter Realâ€Life Study. <i>Oncologist</i> , 2020, 25, e1701-e1710.	3.7	10
17	Continuum of care for advanced biliary tract cancers. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 810-824.	1.5	2
18	Maintenance therapies in metastatic pancreatic cancer: present and future with a focus on PARP inhibitors. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093794.	3.2	12

#	ARTICLE	IF	CITATIONS
19	Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19). <i>European Journal of Cancer</i> , 2020, 141, 62-81.	2.8	122
20	Fluoropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer. <i>International Journal of Cancer</i> , 2020, 147, 3177-3188.	5.1	17
21	FOLFIRINOX de-escalation in advanced pancreatic cancer (aPC): A multicenter real-life study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4639-4639.	1.6	1
22	<scp>FAK</scp> activity in cancer-associated fibroblasts is a prognostic marker and a druggable key metastatic player in pancreatic cancer. <i>EMBO Molecular Medicine</i> , 2020, 12, e12010.	6.9	54
23	Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan. <i>Clinical Colorectal Cancer</i> , 2019, 18, e394-e401.	2.3	13
24	Pancreatic cancer: Best supportive care. <i>Presse Medicale</i> , 2019, 48, e175-e185.	1.9	21
25	Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations. <i>European Journal of Cancer</i> , 2019, 111, 94-106.	2.8	36
26	Schwann cells support oncogenic potential of pancreatic cancer cells through TGF $\beta$ 2 signaling. <i>Cell Death and Disease</i> , 2019, 10, 886.	6.3	40
27	Mechanistic Signatures of Human Papillomavirus Insertions in Anal Squamous Cell Carcinomas. <i>Cancers</i> , 2019, 11, 1846.	3.7	19
28	Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions. , 2019, 7, 333.		129
29	Optimal oncologic management and mTOR inhibitor introduction are safe and improve survival in kidney and liver allograft recipients with <i>de novo</i> carcinoma. <i>International Journal of Cancer</i> , 2019, 144, 886-896.	5.1	22
30	Modified FOLFIRINOX versus CisGem first-line chemotherapy for locally advanced non resectable or metastatic biliary tract cancer (AMEBICA)-PRODIGE 38: Study protocol for a randomized controlled multicenter phase II/III study. <i>Digestive and Liver Disease</i> , 2019, 51, 318-320.	0.9	49
31	Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma. <i>Journal of Pathology</i> , 2019, 248, 51-65.	4.5	215
32	Body composition and sarcopenia: The next-generation of personalized oncology and pharmacology?. , 2019, 196, 135-159.		100
33	Cholangiocarcinoma: the quest for a second-line systemic treatment. <i>Translational Cancer Research</i> , 2019, 8, S275-S288.	1.0	4
34	A randomized noncomparative phase II study of maintenance therapy with multiepitope vaccine Tedopi (OSE2101) ± nivolumab or FOLFIRI after induction chemotherapy (CT) with FOLFIRINOX in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC) (TEDOPaMâ€“PRODIGE 63 GERCOR D17-01) Tj ETQq0 0 0 rgBT /Overlock 10	1.6	8
35	Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers part 2: Neuroendocrine tumours, hepatocellular carcinoma, and gastro-intestinal stromal tumours. , 2018, 181, 49-75.		9
36	Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE,) Tj ETQq0 0 0 rgBT /Overlock 10 Tt	0.9	104

#	ARTICLE	IF	CITATIONS
37	Prognostic stratification of resected pancreatic ductal adenocarcinoma: Past, present, and future. <i>Digestive and Liver Disease</i> , 2018, 50, 979-990.	0.9	22
38	Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?. <i>World Journal of Gastroenterology</i> , 2018, 24, 2137-2151.	3.3	99
39	Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas. , 2017, 174, 145-172.		22
40	Polymerase proofreading domain mutations: New opportunities for immunotherapy in hypermutated colorectal cancer beyond MMR deficiency. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 113, 242-248.	4.4	68
41	Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	35
42	Digestive System Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms. <i>Neuroendocrinology</i> , 2017, 105, 412-425.	2.5	119
43	Predictive Biomarkers of Response to mTOR Inhibitors. , 2016, , 217-228.		1
44	First-line antiangiogenics for metastatic renal cell carcinoma: A systematic review and network meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 107, 44-53.	4.4	25
45	Pancreatic ductal adenocarcinoma in BRCA2 mutation carriers. <i>Endocrine-Related Cancer</i> , 2016, 23, T57-T67.	3.1	16
46	Severe hyponatremia caused by nab-paclitaxel-induced syndrome of inappropriate antidiuretic hormone secretion. <i>Medicine (United States)</i> , 2016, 95, e4006.	1.0	3
47	Efficacy of a sequential treatment strategy with GEMOX-based followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers. <i>Acta Oncologica</i> , 2016, 55, 1168-1174.	1.8	18
48	Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib. <i>Oncotarget</i> , 2016, 7, 38467-38486.	1.8	31
49	Targeting pancreatic stellate cells to improve pancreatic cancer radiosensitivity. <i>Translational Cancer Research</i> , 2016, 5, S730-S737.	1.0	0
50	Contribution and limits of a non-invasive Raman spectroscopic method compared with HPLC for routine application to pre-delivery analytical control of two major camptothecin analogs: irinotecan and topotecan. <i>Journal of Raman Spectroscopy</i> , 2015, 46, 1283-1290.	2.5	7
51	High Met expression in stage pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis. <i>Histopathology</i> , 2015, 67, 664-676.	2.9	21
52	Rationale and design of the Adapted Physical Activity in advanced Pancreatic Cancer patients (APACaP) GERCOR (Groupe Coopérateur Multidisciplinaire en Oncologie) trial: study protocol for a randomized controlled trial. <i>Trials</i> , 2015, 16, 454.	1.6	17
53	Disease control with sunitinib in advanced intrahepatic cholangiocarcinoma resistant to gemcitabine-oxaliplatin chemotherapy. <i>World Journal of Hepatology</i> , 2015, 7, 910.	2.0	6
54	State of the art and future directions of pancreatic ductal adenocarcinoma therapy. , 2015, 155, 80-104.		82

#	ARTICLE	IF	CITATIONS
55	Targeting the TGF $\beta$ pathway for cancer therapy. , 2015, 147, 22-31.		513
56	Targeting cancer cell metabolism in pancreatic adenocarcinoma. Oncotarget, 2015, 6, 16832-16847.	1.8	100
57	Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in <i> vivo</i> whole tumor tissue samples from patients. Oncotarget, 2015, 6, 21614-21627.	1.8	84
58	Perspectives of TGF- $\beta$ inhibition in pancreatic and hepatocellular carcinomas. Oncotarget, 2014, 5, 78-94.	1.8	125
59	Overcoming Resistance to Targeted Therapies: The Next Challenge in Pancreatic Neuroendocrine Tumors (PNETs) Treatment. , 2014, , 167-180.		0
60	Unraveling galectin-1 as a novel therapeutic target for cancer. Cancer Treatment Reviews, 2014, 40, 307-319.	7.7	174
61	MEK in cancer and cancer therapy. , 2014, 141, 160-171.		200
62	Is primary tumor resection associated with a longer survival in colon cancer and unresectable synchronous metastases? A 4-year multicentre experience. European Journal of Surgical Oncology, 2014, 40, 685-691.	1.0	25
63	Primary tumor resection in colorectal cancer with unresectable synchronous metastases: A review. World Journal of Gastrointestinal Oncology, 2014, 6, 156.	2.0	48
64	Angiogenesis Inhibition Using Sunitinib in Pancreatic Neuroendocrine Tumors. , 2014, , 127-140.		0
65	Advances with Somatostatin Analogs in Neuroendocrine Tumors; The Promise of Radionuclides in Neuroendocrine Tumors. , 2014, , 43-63.		0
66	Targeting the Ras $\rightarrow$ ERK pathway in pancreatic adenocarcinoma. Cancer and Metastasis Reviews, 2013, 32, 147-162.	5.9	83
67	Stromal expression of SPARC in pancreatic adenocarcinoma. Cancer and Metastasis Reviews, 2013, 32, 585-602.	5.9	104
68	Prolonged Survival in a Patient with Neuroendocrine Tumor of the Cecum and Diffuse Peritoneal Carcinomatosis. Case Reports in Gastroenterology, 2012, 6, 205-210.	0.6	6
69	New treatment options with cytotoxic agents in neuroendocrine tumours. Targeted Oncology, 2012, 7, 169-172.	3.6	7
70	Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies. Targeted Oncology, 2012, 7, 173-181.	3.6	26
71	FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts. World Journal of Gastroenterology, 2012, 18, 4533.	3.3	41
72	Intramural duodenal hematoma as a complication of paraduodenal pancreatitis. Clinics and Research in Hepatology and Gastroenterology, 2011, 35, 140-141.	1.5	5

#	ARTICLE	IF	CITATIONS
73	Gastric Juvenile Polyposis with High-Grade Dysplasia in Pachydermoperiostosis. Case Reports in Gastroenterology, 2011, 5, 508-515.	0.6	2
74	Difficult Diagnosis of Atypical Cystic Pancreatic Lesions in von Hippel-Lindau Disease. Journal of Computer Assisted Tomography, 2010, 34, 140-145.	0.9	7
75	Autoimmune pancreatitis with atypical imaging findings that mimicked an endocrine tumor. World Journal of Gastroenterology, 2010, 16, 2954.	3.3	3
76	Modulation of Collagen and MMP-1 Gene Expression in Fibroblasts by the Immunosuppressive Drug Rapamycin. Journal of Biological Chemistry, 2006, 281, 33045-33052.	3.4	67